Research programme: neurostabilising therapeutics - Cambria Pharmaceuticals
Alternative Names: CMB-00208; CMB-00294; CMB-00792; CMB-44349Latest Information Update: 16 Jul 2016
At a glance
- Originator Cambria Biosciences LLC
- Developer Cambria Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 17 May 2007 Preclinical trials in Epilepsy in USA (unspecified route)